Semaglutide B 3.0 mg/ml PDS290 clinical trials

Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial.

This study is looking at new treatments for a liver condition called NASH. Researchers want to see if combining two medicines can improve liver scarring and damage. They will also check if the treatments are safe for people with NASH.